爱尔眼科 reported revenue of ¥11.95B for the period ended 2026-06-30, +3.8% year on year. Net income was ¥1.54B, a 12.9% net margin on a 46.1% gross margin. The largest revenue line is 屈光项目 at 41% of the total. Free cash flow for the period was ¥0.92B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥11.95B | +3.8% |
| Gross profit | ¥5.51B | — |
| Operating income | ¥2.82B | — |
| Net income | ¥1.54B | -30.5% |
| Gross margin | 46.1% | Net margin 12.9% |
| Revenue Q/Q | -13.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 屈光项目 | ¥4.91B | 41.1% |
| 视光服务项目 | ¥2.89B | 24.2% |
| 白内障项目 | ¥1.79B | 14.9% |
| 眼前段项目 | ¥1.07B | 8.9% |
| 眼后段项目 | ¥0.80B | 6.7% |
| 其他项目 | ¥0.47B | 3.9% |
| 其他(补充) | ¥0.03B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥6.44B | 53.9% |
| R&D | ¥0.12B | 1.0% |
| SG&A | ¥2.38B | 19.9% |
| Tax & other | ¥1.28B | 10.7% |
| Item | Amount |
|---|---|
| Total assets | ¥36.24B |
| Total liabilities | ¥11.80B |
| Shareholders' equity | ¥24.44B |
| Equity / assets | 67.4% |
| Operating cash flow | ¥1.21B |
| Capital expenditure | ¥0.30B |
| Free cash flow | ¥0.92B |
| Cash conversion (OCF / net income) | 189% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
同花顺 ・ 东方财富 ・ 智飞生物 ・ 汇川技术 ・ 光线传媒 ・ 阳光电源 ・ 中际旭创 ・ 晶盛机电 ・ 天孚通信 ・ 三环集团 ・ 芒果超媒 ・ 昆仑万维
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies